SLNO Q2 2018 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$3M

Net Income

-$8M

EPS (Diluted)

$-5.63

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$179,000

Balance Sheet

Total Assets

$33M

Total Liabilities

$18M

Stockholders' Equity

$16M

Cash & Equivalents

$13M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$1,000	-100.0%
Gross Profit	$0	-$41,000	+100.0%
Operating Income	-$3M	-$3M	-6.3%
Net Income	-$8M	-$4M	-92.6%